MI, N., CE, A., E, R., TB, T., M, A., T, V., . . . PR, L. (2016). Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study. Pharmaceutical research, 33(12), 2930. https://doi.org/10.1007/s11095-016-2015-0
Chicago Style (17th ed.) CitationMI, Nounou, Adkins CE, Rubinchik E, Terrell-Hall TB, Afroz M, Vitalis T, Gabathuler R, Tian MM, and Lockman PR. "Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study." Pharmaceutical Research 33, no. 12 (2016): 2930. https://doi.org/10.1007/s11095-016-2015-0.
MLA (9th ed.) CitationMI, Nounou, et al. "Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: An In-Vivo Study." Pharmaceutical Research, vol. 33, no. 12, 2016, p. 2930, https://doi.org/10.1007/s11095-016-2015-0.
